https://www.live-feeds.com/feed/patients-switching-to-novo-nordisk-s-wegovy-pill-from-shots-lose-more-weight-in-real-world-studyContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/patients-switching-to-novo-nordisk-s-wegovy-pill-from-shots-lose-more-weight-in-real-world-studyhttps://www.live-feeds.com/feed/patients-switching-to-novo-nordisk-s-wegovy-pill-from-shots-lose-more-weight-in-real-world-study#u98674Sun, 04 Oct 2026 12:05:34 +0000Adults with overweight or obesity who transitioned from injectable GLP-1 treatments to once-daily oral semaglutide, known as the Wegovy pill, shed an average of 4.1 percent of their body weight after three months. Findings from the OCTANE real-world analysis were presented at the EASD 2026 conference. The results suggest patients may not require lifelong weekly injections and can instead utilize more convenient daily oral treatments. Novo Nordisk also announced a research collaboration with Ro to generate additional real-world evidence for the oral medication, while continuing to present liver